Short Interest in Pharvaris N.V. (NASDAQ:PHVS) Decreases By 17.4%

Pharvaris N.V. (NASDAQ:PHVS) saw a large decline in short interest in January. As of January 30th, there was short interest totaling 746,902 shares, a decline of 17.4% from the January 15th total of 904,318 shares. Based on an average daily volume of 150,463 shares, the short-interest ratio is presently 5.0 days. Based on an average daily volume of 150,463 shares, the short-interest ratio is presently 5.0 days.

Pharvaris Stock Performance

Shares of PHVS traded down $0.15 during trading hours on Monday, hitting $26.45. The stock had a trading volume of 92,452 shares, compared to its average volume of 128,811. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.80. The stock has a fifty day moving average price of $26.06 and a 200 day moving average price of $24.32.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP purchased a new position in shares of Pharvaris in the third quarter worth approximately $43,282,000. Paradigm Biocapital Advisors LP raised its position in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares during the period. Balyasny Asset Management L.P. purchased a new position in shares of Pharvaris during the 3rd quarter worth $15,613,000. Commodore Capital LP grew its position in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period. Finally, General Atlantic L.P. grew its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Guggenheim upped their target price on shares of Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Morgan Stanley upped their price objective on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Bank of America increased their target price on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Wednesday, December 3rd. Finally, Leerink Partners set a $38.00 price objective on Pharvaris in a research report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.56.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.